Challenges and Opportunities to Manage Depression During the Menopausal Transition and Beyond

Psychiatric Clinics of North America

Volumn 33, Issue 2, 2010, Pages 295-308

  Soares, Claudio N ^a,b   Frey, Benicio N ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Women's Health Concerns Clinic   (Canada)

Author keywords

Anxiety; Depression; Estrogen; Menopause; Perimenopause; Vasomotor symptoms

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CALCIUM; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DULOXETINE; ESCITALOPRAM; ESTRADIOL; ESTROGEN RECEPTOR; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYPERICUM REVOLUTUM EXTRACT; ISOFLAVONE; KAVA EXTRACT; MIRTAZAPINE; PAROXETINE; PLACEBO; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TIBOLONE; TRAZODONE; VENLAFAXINE;

ADJUVANT THERAPY; ANXIETY DISORDER; CLIMACTERIUM; CLINICAL TRIAL; DEPRESSION; DISTRESS SYNDROME; DYSTHYMIA; HORMONE SUBSTITUTION; HUMAN; INVOLUTIONAL DEPRESSION; LIVER TOXICITY; MAJOR DEPRESSION; MENOPAUSAL SYNDROME; NEUROTRANSMISSION; OVARIECTOMY; POSTMENOPAUSE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; REMISSION; REVIEW; RISK FACTOR; VASOMOTOR DISORDER;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; LIFE CHANGE EVENTS; MALE; MENOPAUSE; MIDDLE AGED; PREMENSTRUAL SYNDROME; RISK FACTORS; SLEEP DISORDERS; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951472217     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2010.01.007     Document Type: Review

References (77)

1. Kessler R.C., McGonagle K.A., Swartz M., et al. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993, 29(2-3):85-96.
2. Birmaher B., Ryan N.D., Williamson D.E., et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996, 35(11):1427-1439.
3. Bebbington P., Dunn G., Jenkins R., et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Int Rev Psychiatry 2003, 15(1-2):74-83.
4. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51(1):8-19.
5. McEwen B.S. Invited review. Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Phys 2001, 91(6):2785-2801.
6. Morrison J.H., Brinton R.D., Schmidt P.J., et al. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 2006, 26(41):10332-10348.
7. McEwen B.S., Alves S.E. Estrogen actions in the central nervous system. Endocr Rev 1999, 20(3):279-307.
8. Deecher D., Andree T.H., Sloan D., et al. From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 2008, 33(1):3-17.
9. Freedman R.R. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005, 23(2):117-125.
10. Santoro N. The menopausal transition. Am J Med 2005, 118(Suppl 12B):8-13.
11. Nelson H.D. Menopause. Lancet 2008, 371(9614):760-770.
12. Soares C.N. Depression during the menopausal transition: window of vulnerability or continuum of risk?. Menopause 2008, 15(2):207-209.
13. Soares C.N., Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?. J Psychiatry Neurosci 2008, 33(4):331-343.
14. Soares C.N., Almeida O.P., Joffe H., et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001, 58(6):529-534.
15. Schmidt P.J., Nieman L., Danaceau M.A., et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000, 183(2):414-420.
16. Amore M., Di Donato P., Berti A., et al. Sexual and psychological symptoms in the climacteric years. Maturitas 2007, 56(3):303-311.
17. Bromberger J.T., Meyer P.M., Kravitz H.M., et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health 2001, 91(9):1435-1442.
18. Juang K.D., Wang S.J., Lu S.R., et al. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas 2005, 52(2):119-126.
19. Slaven L., Lee C. Mood and symptom reporting among middle-aged women: the relationship between menopausal status, hormone replacement therapy, and exercise participation. Health Psychol 1997, 16(3):203-208.
20. Baker A., Simpson S., Dawson D. Sleep disruption and mood changes associated with menopause. J Psychosom Res 1997, 43(4):359-369.
21. Kloss J.D., Tweedy K., Gilrain K. Psychological factors associated with sleep disturbance among perimenopausal women. Behav Sleep Med 2004, 2(4):177-190.
22. Thurston R.C., Blumenthal J.A., Babyak M.A., et al. Association between hot flashes, sleep complaints, and psychological functioning among healthy menopausal women. Int J Behav Med 2006, 13(2):163-172.
23. Joffe H., Soares C.N., Thurston R.C., et al. Depression is associated with worse objectively and subjectively measured sleep, but not more frequent awakenings, in women with vasomotor symptoms. Menopause 2009, 16(4):671-679.
24. Binfa L., Castelo-Branco C., Blumel J.E., et al. Influence of psycho-social factors on climacteric symptoms. Maturitas 2004, 48(4):425-431.
25. Malacara J.M., Canto de Cetina T., Bassol S., et al. Symptoms at pre- and postmenopause in rural and urban women from three States of Mexico. Maturitas 2002, 43(1):11-19.
26. Avis N.E., Brambilla D., McKinlay S.M., et al. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994, 4(3):214-220.
27. Bromberger J.T., Matthews K.A., Schott L.L., et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord 2007, 103(1-3):267-272.
28. Freeman E.W., Sammel M.D., Liu L., et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004, 61(1):62-70.
29. Maartens L.W., Knottnerus J.A., Pop V.J. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas 2002, 42(3):195-200.
30. Woods N.F., Smith-DiJulio K., Percival D.B., et al. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Menopause 2008, 15(2):223-232.
31. Kaufert P.A., Gilbert P., Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas 1992, 14(2):143-155.
32. Cohen L.S., Soares C.N., Vitonis A.F., et al. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2006, 63(4):385-390.
33. Freeman E.W., Sammel M.D., Lin H., et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006, 63(4):375-382.
34. Bloch M., Schmidt P.J., Danaceau M., et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000, 157(6):924-930.
35. Rocca W.A., Grossardt B.R., Geda Y.E., et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008, 15(6):1050-1059.
36. Freeman E.W., Sammel M.D., Lin H., et al. The role of anxiety and hormonal changes in menopausal hot flashes. Menopause 2005, 12(3):258-266.
37. Freeman E.W., Sammel M.D., Lin H., et al. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008, 111(1):127-136.
38. Gold E.B., Colvin A., Avis N., et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006, 96(7):1226-1235.
39. Morrison M.F., Kallan M.J., Ten Have T., et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004, 55(4):406-412.
40. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
41. Hackley B., Rousseau M.E. CEU: managing menopausal symptoms after the women's health initiative. J Midwifery Womens Health 2004, 49(2):87-95.
42. Kessel B., Kronenberg F. The role of complementary and alternative medicine in management of menopausal symptoms. Endocrinol Metab Clin North Am 2004, 33(4):717-739.
43. McIntyre R.S., Konarski J.Z., Grigoriadis S., et al. Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ 2005, 172(1):57-59.
44. Joffe H., Soares C.N., Petrillo L.F., et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007, 68(6):943-950.
45. Soares C.N., Poitras J.R., Prouty J., et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003, 64(4):473-479.
46. Evans M.L., Pritts E., Vittinghoff E., et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005, 105(1):161-166.
47. Speroff L., Gass M., Constantine G., et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008, 111(1):77-87.
48. Stearns V., Beebe K.L., Iyengar M., et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003, 289(21):2827-2834.
49. Soares C.N., Arsenio H., Joffe H., et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006, 13(5):780-786.
50. Joffe H., Groninger H., Soares C.N., et al. An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. J Womens Health Gend Based Med 2001, 10(10):999-1004.
51. Thase M.E., Entsuah R., Cantillon M., et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005, 14(7):609-616.
52. Osmers R., Friede M., Liske E., et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005, 105(5 Pt 1):1074-1083.
53. Wuttke W., Jarry H., Christoffel V., et al. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine 2003, 10(4):348-357.
54. Nelson H.D., Vesco K.K., Haney E., et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006, 295(17):2057-2071.
55. Newton K.M., Reed S.D., LaCroix A.Z., et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006, 145(12):869-879.
56. Uebelhack R., Blohmer J.U., Graubaum H.J., et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006, 107(2 Pt 1):247-255.
57. Grube B., Walper A., Wheatley D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin. Adv Ther 1999, 16(4):177-186.
58. Boyle G.J., Murrihy R. A preliminary study of hormone replacement therapy and psychological mood states in perimenopausal women. Psychol Rep 2001, 88(1):160-170.
59. Gambacciani M., Ciaponi M., Cappagli B., et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003, 44(2):157-163.
60. Haines C.J., Yim S.F., Chung T.K., et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas 2003, 44(3):207-214.
61. Khoo S.K., Coglan M., Battistutta D., et al. Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate. Climacteric 1998, 1(1):55-62.
62. Heikkinen J., Vaheri R., Timonen U.A. 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of-life findings. J Br Menopause Soc 2006, 12(3):115-125.
63. Gulseren L., Kalafat D., Mandaci H., et al. Effects of tibolone on the quality of life, anxiety-depression levels and cognitive functions in natural menopause: an observational follow-up study. Aust N Z J Obstet Gynaecol 2005, 45(1):71-73.
64. Baksu A., Ayas B., Citak S., et al. Efficacy of tibolone and transdermal estrogen therapy on psychological symptoms in women following surgical menopause. Int J Gynaecol Obstet 2005, 91(1):58-62.
65. Pansini F., Albertazzi P., Bonaccorsi G., et al. Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms. Clin Exp Obstet Gynecol 1995, 22(4):341-344.
66. Stearns V., Isaacs C., Rowland J., et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000, 11(1):17-22.
67. Ladd C.O., Newport D.J., Ragan K.A., et al. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005, 22(2):94-97.
68. Ushiroyama T., Ikeda A., Ueki M. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. J Med 2004, 35(1-6):151-162.
69. Volz H.P., Murck H., Kasper S., et al. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002, 164(3):294-300.
70. Cagnacci A., Arangino S., Renzi A., et al. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas 2003, 44(2):103-109.
71. De Leo V., la Marca A., Morgante G., et al. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. Maturitas 2001, 39(2):185-188.
72. Geller S.E., Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause 2007, 14(3 Pt 1):541-549.
73. Tode T., Kikuchi Y., Hirata J., et al. Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes. Int J Gynaecol Obstet 1999, 67(3):169-174.
74. Hartley D.E., Elsabagh S., File S.E. Gincosan (a combination of Ginkgo biloba and Panax ginseng): the effects on mood and cognition of 6 and 12 weeks' treatment in post-menopausal women. Nutr Neurosci 2004, 7(5-6):325-333.
75. Nappi R.E., Malavasi B., Brundu B., et al. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005, 20(1):30-35.
76. Andreatini R., Sartori V.A., Seabra M.L., et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002, 16(7):650-654.
77. Casini M.L., Marelli G., Papaleo E., et al. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril 2006, 85(4):972-978.